- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04625322
HCV Treatment Initiation During Acute Psychiatric Admission
INSPIRE: Interventions for Screening and Treatment of Psychiatric Inpatients With HCV Resulting in Elimination
Hepatitis C virus (HCV) disproportionally affects certain populations, including those facing substance use and mental health challenges. In the past, many individuals with mental illness were not treated due to the psychiatric side-effects of interferon. However, the development of highly effective, direct-acting antivirals (DAA) has revolutionized HCV treatment such that cure rates are >95% with 8-12 weeks of simple, safe, and well-tolerated therapy.
A recent systematic review reported that across 13 North American studies, HCV prevalence among people admitted to psychiatric hospitals was a staggering 17.4% (13.2-22.6%). Despite these concerning figures, mental health facilities have not been a focus of HCV elimination efforts to date. The Centre for Addiction and Mental Health (CAMH) in Toronto is the largest mental health facility in Canada, with a psychiatric emergency department seeing ~35 patients per day with many admitted to the acute psychiatric units for safety and stabilization. Currently, psychiatric patients screened for HCV at CAMH have a 75% 'no show' rate at the Toronto Centre for Liver Disease (TCLD), which is located less than 5km away, suggesting that referral upon discharge is ineffective.
This study will be the first trial to evaluate whether it would be feasible and beneficial to initiate treatment during an acute psychiatric admission rather than referring to specialty upon discharge. The combination of broad HCV screening with rapid linkage to treatment has led to successful elimination of HCV within defined populations, so-called micro-elimination. The investigators hypothesize that HCV treatment can be effectively delivered by providers in psychiatric care facilities, which will improve treatment uptake over traditional referral models.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Anticipé)
Phase
- Phase 4
Contacts et emplacements
Coordonnées de l'étude
- Nom: Mia Biondi, NP-PHC, PhD
- Numéro de téléphone: 6476286461
- E-mail: mia.biondi@mail.mcgill.ca
Lieux d'étude
-
-
Ontario
-
Toronto, Ontario, Canada, M6J 1H3
- Recrutement
- Centre for Addiction and Mental Health
-
Contact:
- Renee Logan, MD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Chronic HCV infection, positive HCV RNA
- Aged 18 to 80
- Willingness and capacity to provide informed consent, or consent is provided by a substitute decision maker
Exclusion Criteria:
- Presence of or history of decompensated cirrhosis (evidence of decompensation with history of either ascites, variceal hemorrhage, or hepatic encephalopathy)
- Platelets < 75,000/mm3, total albumin <35 g/L, total bilirubin >34 μmol/L, INR >1.5
- History of current or past hepatocellular carcinoma.
- HBV (HBsAg +ve) co-infection or untreated HIV co-infection
- Prior HCV antiviral therapy with DAA with or without peginterferon/ribavirin
- Chronic liver disease other than mild nonalcoholic or alcoholic fatty liver disease from a cause other than HCV
- Pregnancy/breastfeeding/inability to use contraception
- Use of concomitant contraindicated medications
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Aucune intervention: Referral to outpatient specialty for HCV care
Acute psychiatric patients who test HCV RNA positive by OraQuick HCV Antibody Test will be referred for outpatient specialty follow-up at the Toronto Centre for Liver Disease (TCLD) where they will be assessed and offered treatment as per standard of care.
TCLD referrals are triaged by clinicians unaware of the trial and prioritized based on urgency of treatment.
Patients who do not attend the initial visit will be rescheduled.
After 3 'no-show' visits, the person will not be scheduled again at TCLD and will be deemed a 'treatment failure' for the trial with subsequent HCV follow-up at the discretion of the CAMH provider, consistent with current practice.
|
|
Expérimental: Receive HCV care during inpatient admission by a hospitalist
CAMH hospitalists covering the inpatient units will undergo a training designed for non-specialist providers, used in the ASCEND trial, which has already occurred.
An algorithm-based work-up which has been used for non-specialist treaters in ECHO Liver, a Ministry-of-Health supported tele-mentoring program, will then be completed for all who test HCV RNA positive.
Labs will be drawn by the hospital phlebotomist following a positive HCV RNA result from the Gene Xpert Viral Load Assay.
At this time, a sample will also be obtained to send to for conventional HCV RNA quantification and genotyping.
|
HCV diagnosis and treatment will be conducted by a hospitalist during an acute psychiatric admission at CAMH
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
SVR12 by intention to treat (ITT) in each arm
Délai: 24 months
|
To determine whether screening for HCV using rapid diagnostics during an acute psychiatric admission with inpatient initiation of HCV treatment is superior to standard post-discharge referral and treatment by intention to treat (ITT).
|
24 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
SVR12 by modified intention to treat (mITT) in each arm
Délai: 24 months
|
To determine whether screening for HCV using rapid diagnostics during an acute psychiatric admission with inpatient initiation of HCV treatment is superior to standard post-discharge referral and treatment by modified intention to treat (mITT).
|
24 months
|
HCV relapse rate
Délai: 24 months
|
To compare the HCV viral relapse rate in both arms (re-appearance of HCV RNA in those undetectable at end of treatment; relapse distinguished from reinfection by sequencing of the recurrent HCV RNA and comparing to baseline).
|
24 months
|
HCV seroprevalence rates
Délai: 12 months
|
To determine HCV seroprevalence rates among acute vs addictions patients admitted to CAMH.
|
12 months
|
HCV RNA positivity rates
Délai: 12 months
|
To determine HCV RNA positivity rates among acute vs addictions patients admitted to CAMH.
|
12 months
|
CAMH staff acceptability of POC antibody and RNA testing
Délai: 12 months
|
CAMH staff involved in the trial will be asked to particiapte in an acceptibility survey regarding rapid POC antibody and RNA testing on the acute units.
|
12 months
|
Concordance of POC HCV RNA with HCV RNA by phlebotomy
Délai: 12 months
|
To determine concordance of POC HCV RNA (GeneXpert) with HCV RNA by phlebotomy (Abbott RealTime).
|
12 months
|
Minimum and mean times from diagnosis to treatment initiation
Délai: 24 months
|
Evaluate the mean and minimum times to treatment initiation in both arms, and compare.
|
24 months
|
Adherence with out-patient follow-up visits
Délai: 24 months.
|
Evaluate and compare out-patient follow-up visit adherence in both arms.
|
24 months.
|
Adherence to HCV treatment, by HCV regimen
Délai: 24 months.
|
Evaluate and compare both arms for medication adherence (patient self-report and pill count), and variance by medication regimen.
|
24 months.
|
Adverse events while on HCV treatment
Délai: 18 months.
|
To determine and compare adverse events in both arms while patients are on treatment.
|
18 months.
|
HCV Reinfection
Délai: 24 months.
|
Reinfection rates by the end of the defined as HCV RNA detectability after prior SVR with demonstration of distinct viral sequence from baseline sample to distinguish
|
24 months.
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 20-5188
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .